Synosia reports early clinical data for Parkinson's candidate
This article was originally published in Scrip
Synosia Therapeutics has reported some potentially positive interim results from a Phase IIa study investigating its experimental adenosine 2a (A2a) receptor antagonist SYN-115 as an adjunctive therapy to levodopa in Parkinson's disease.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.